Improvements in variant detection
AssigneeCancer Research Technology Limited
InventorsEyal Fisher, Katrin Heider, Charles Massie, Florent Mouliere, Nitzan Rosenfeld, Christopher G. Smith, Jonathan C.M. Wan
Life of this patent
Estimating the term…
Loading patent…
AssigneeCancer Research Technology Limited
InventorsEyal Fisher, Katrin Heider, Charles Massie, Florent Mouliere, Nitzan Rosenfeld, Christopher G. Smith, Jonathan C.M. Wan
Estimating the term…
The present invention provides a computer-implemented method for detecting cell-free DNA (cfDNA), such as circulating tumour DNA, in a DNA-containing sample obtained from a patient, the method comprising: (a) providing loci of interest comprising at least 2 mutation-containing loci representative of a tumour of the patient (“patient-specific loci”); (b) providing sequence data comprising sequence reads of a plurality of polynucleotide fragments from a DNA-containing sample from the patient, wherein said sequence reads span said at least 2 mutation-containing loci of step (a); (c) optionally, performing reads collapsing to group the sequence reads into read families; (d) calculating the mutant allele fraction across some or all of said at least 2 patient-specific loci, optionally wherein the mutant allele fraction is calculated by aggregating mutant reads and total reads; (e) classifying the sample as containing or not containing the target cfDNA based on the calculated mutant allele fraction. Also provided a related methods and systems.
A computer-implemented method for detecting cell-free DNA (cf DNA), such as circulating tumour DNA (ctDNA), in a DNA-containing sample obtained from a patient, the method comprising:
The method according to any one of the preceding claims, wherein the sequence data comprising sequence reads obtained in step (b) represent Tailored Panel Sequencing (TAPAS) sequence reads, focussed-exome sequence reads, whole-exome sequence reads or whole-genome sequence reads.
The method according to any one of the preceding claims, wherein the sequence data comprising sequence reads provided in step (b) represent sequence reads of multiple DNA fragments from a substantially cell-free liquid sample from the patient.
The method according to any one of the preceding claims, wherein said at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 mutation-containing loci representative of a tumour of the patient have been obtained by sequencing DNA obtained directly from a tumour sample from the patient or sequencing DNA obtained from a liquid, e.g., plasma sample from the patient at a time of high tumour disease burden.
The method according to any one of the preceding claims, wherein the sequence data comprising sequence reads obtained in step (b) represent sequence reads of a plurality of polynucleotide fragments from a sample obtained from the patient after the patient has begun a course of treatment of the tumour and/or after the patient has had surgical resection of the tumour,
The method according to any one of the preceding claims, wherein the patient has, or has had, melanoma, lung cancer, bladder cancer, oesophageal cancer, colorectal cancer, ovarian cancer brain cancer, and/or breast cancer.
The method according to any one of the preceding claims, wherein the reads collapsing step (c) comprises grouping reads into read families based on fragment start and end position and at least one molecular barcode,
The method according to any one of the preceding claims, wherein the sequence reads are size-selected in silico for reads within the size ranges 115-160 bp, 115-190 bp, 250-400 bp and 440-460 bp in order to enrich for those reads representing ctDNA.
The method according to any one of the preceding claims, wherein said performing reads collapsing further comprises applying at least one minimal residual disease (MRD) filter selected from the group consisting of:
A computer-implemented method for detecting a target polynucleotide in a sample in which the target polynucleotide is a minor fraction of the total polynucleotide in the sample, wherein the target polynucleotide and the non-target polynucleotide differ in sequence at a plurality of loci, the method comprising:
A method according to any one of the preceding claims, wherein the analysis of the sample includes a size-selection step which separates out different fragment sizes of DNA.
A method according to any one of the preceding claims, wherein the sample obtained from the patient is a limited volume sample comprising less than one tumour-derived haploid genome or wherein the sequencing data from the sample represents sequencing coverage or depth of less than 1, 2, 3, 4, 10 or 20 haploid genomes.
A method according to any one of the preceding claims, wherein the sample obtained from the patient is a limited volume sample selected from the group consisting of:
A method according to any one of the preceding claims, wherein the sample obtained from the patient is:
A method according to any one of the preceding claims, wherein the patient is healthy or has a disease (e.g. a cancer) and/or wherein the patient is human or a non-human animal (e.g. a rodent).
The method according to any one of the preceding claims, wherein the method comprises a step of suppressing outlier noise at a locus that is not consistent with the remaining distribution of patient-specific mutant signal in that sample.
The method according to any one of the preceding claims, wherein the likelihood of ctDNA presence in the sample is determined by the generalized likelihood ratio:
A system for detecting target cell-free DNA (cfDNA) in a DNA-containing sample obtained from a patient, comprising:
A non-transitory computer readable medium for detecting target cell-free DNA (cfDNA) in a DNA-containing sample obtained from a patient, comprising instructions that, when executed by at least one processor, cause the at least one processor to perform operations comprising:
Dependencies are inferred from the claim text.